After a 7-year run as the only show in town, Botox could soon face some competition. Awaiting FDA approval, Reloxin—the US version of a French product called Dysport—is being marketed as a quicker and longer-lasting treatment for botulinum toxin fans. But doctors themselves are confused about what differences, if any, exist between the wrinkle-smoothers, the New York Times reports.
Some docs use the drugs for different wrinkles, but see little disparity. Others purport that, with a practiced hand, they need less of Dysport to produce the same results as Botox. With each dose at more than $250, that could be a hefty savings. But Dysport novices, as many US doctors will be, may fumble until they figure out the proper dosages. (Read more Botox stories.)